A phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

Thumbnail
Name:
s00280-018-3558-z.pdf
Size:
823.6Kb
Format:
PDF
Description:
Full text, Open Access article
Download
Authors
Dean, Emma J
Banerji, U
Schellens, J
Krebs, Matthew G
Jimenez, B
van Brummelen, E
Bailey, C
Casson, E
Cripps, D
Cullberg, M
Evans, S
Foxley, A
Lindemann, J
Rugman, P
Taylor, N
Turner, G
Yates, J
Lawrence, P
Affiliation
The Christie NHS Foundation Trust, The University of Manchester, Manchester, UK
Issue Date
2018-03-14

Metadata
Show full item record
Abstract
AZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect of food (Part B) on the PK/safety of the tablet.
Citation
A phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. 2018, Cancer Chemother Pharmacol
Journal
Cancer Chemotherapy and Pharmacology
URI
http://hdl.handle.net/10541/620904
DOI
10.1007/s00280-018-3558-z
PubMed ID
29541803
Type
Article
Language
en
ISSN
1432-0843
Collections